<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00834392</url>
  </required_header>
  <id_info>
    <org_study_id>H2008:035</org_study_id>
    <nct_id>NCT00834392</nct_id>
  </id_info>
  <brief_title>Exercise in Men With Prostate Cancer</brief_title>
  <official_title>A Pilot Study of Exercise in Men With Prostate Cancer Receiving Androgen Depletion Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Manitoba Medical Service Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pilot study is to compare a walking exercise program (Exercise Group) to
      standard medical care (Control Group) in prostate cancer survivors receiving androgen
      depletion therapy (ADT). The central hypothesis of the proposed research is that the walking
      exercise program will have a positive impact on the bone health, health-related quality of
      life, and physical function of men with prostate cancer receiving ADT.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bone health</measure>
    <time_frame>baseline, 12 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Exercise</intervention_name>
    <description>Walking exercise</description>
    <arm_group_label>Exercise</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  men aged 50 years or older

          -  diagnosed with adenocarcinoma prostate cancer

          -  will initiate and receive continuous ADT (luteinizing hormone releasing hormone
             agonist (LHRH) or combination of LHRH and anti-androgen) for at least 12 months after
             recruitment

          -  Patients will also consent to participating in the study.

        Exclusion Criteria:

          -  severe cardiac disease (New York Heart Association class III or greater)

          -  angina

          -  severe osteoporosis

          -  uncontrolled hypertension (blood pressure &gt; 160/95mm Hg)

          -  orthostatic blood pressure drop &gt; 20mm Hg

          -  moderate to severe aortic stenosis

          -  acute illness or fever

          -  uncontrolled atrial or ventricular dysrhythmias

          -  uncontrolled sinus tachycardia (&gt; 120 beats per minute)

          -  uncontrolled congestive heart failure third-degree atrio-ventricular heart block,
             active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein
             thrombosis, resting ST displacement (&gt; 3mm), uncontrolled diabetes, uncontrolled pain,
             cognitive impairment, history of falls due to balance impairment or lost of
             consciousness, severe neuromusculoskeletal conditions that limit their ability to
             perform walking exercise (including ataxia, peripheral or sensory neuropathy, unstable
             bone lesion, severe arthritis, pathological lower limb fractures within 6 months,
             lower limb amputation).
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. Ellen Lee, PhD, PT</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Y.K. James Lau, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CancerCare Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0T6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2009</study_first_posted>
  <last_update_submitted>January 31, 2011</last_update_submitted>
  <last_update_submitted_qc>January 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2011</last_update_posted>
  <responsible_party>
    <name_title>C. Ellen Lee, PhD, PT, Assistant Professor</name_title>
    <organization>University of Manitoba</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

